162 related articles for article (PubMed ID: 29791034)
1. High expression of CD10 in anaplastic thyroid carcinomas.
Nakazawa T; Kondo T; Vuong HG; Odate T; Kawai M; Tahara I; Kasai K; Inoue T; Oishi N; Mochizuki K; Ito K; Katoh R
Histopathology; 2018 Sep; 73(3):492-499. PubMed ID: 29791034
[TBL] [Abstract][Full Text] [Related]
2. CD10 expression is useful in the diagnosis of follicular carcinoma and follicular variant of papillary thyroid carcinoma.
Tomoda C; Kushima R; Takeuti E; Mukaisho K; Hattori T; Kitano H
Thyroid; 2003 Mar; 13(3):291-5. PubMed ID: 12729479
[TBL] [Abstract][Full Text] [Related]
3. Long Non-coding RNA Expression in Anaplastic Thyroid Carcinomas.
Wang Y; Hardin H; Chu YH; Esbona K; Zhang R; Lloyd RV
Endocr Pathol; 2019 Dec; 30(4):262-269. PubMed ID: 31468286
[TBL] [Abstract][Full Text] [Related]
4. Expression profile of biomarkers altered in papillary and anaplastic thyroid carcinoma: Contribution of Tunisian patients.
Fourati A; El Amine O; Ben Ayoub W; Cherni I; Goucha A; El May MV; Gamoudi A; El May A
Bull Cancer; 2017 May; 104(5):433-441. PubMed ID: 28185633
[TBL] [Abstract][Full Text] [Related]
5. Can CD10 be used as a diagnostic marker in thyroid pathology?
Yegen G; Demir MA; Ertan Y; Nalbant OA; Tunçyürek M
Virchows Arch; 2009 Jan; 454(1):101-5. PubMed ID: 19031085
[TBL] [Abstract][Full Text] [Related]
6. Napsin A expression in anaplastic, poorly differentiated, and micropapillary pattern thyroid carcinomas.
Chernock RD; El-Mofty SK; Becker N; Lewis JS
Am J Surg Pathol; 2013 Aug; 37(8):1215-22. PubMed ID: 23681073
[TBL] [Abstract][Full Text] [Related]
7. Expression of cancer stem cell markers and epithelial-mesenchymal transition-related factors in anaplastic thyroid carcinoma.
Jung CW; Han KH; Seol H; Park S; Koh JS; Lee SS; Kim MJ; Choi IJ; Myung JK
Int J Clin Exp Pathol; 2015; 8(1):560-8. PubMed ID: 25755746
[TBL] [Abstract][Full Text] [Related]
8. Expression of epithelial-mesenchymal transition regulators SNAI2 and TWIST1 in thyroid carcinomas.
Buehler D; Hardin H; Shan W; Montemayor-Garcia C; Rush PS; Asioli S; Chen H; Lloyd RV
Mod Pathol; 2013 Jan; 26(1):54-61. PubMed ID: 22899291
[TBL] [Abstract][Full Text] [Related]
9. HGF/C-MET system pathways in benign and malignant histotypes of thyroid nodules: an immunohistochemical characterization.
Ruggeri RM; Vitarelli E; Barresi G; Trimarchi F; Benvenga S; Trovato M
Histol Histopathol; 2012 Jan; 27(1):113-21. PubMed ID: 22127603
[TBL] [Abstract][Full Text] [Related]
10. A study of FoxA1 expression in thyroid tumors.
Nonaka D
Hum Pathol; 2017 Jul; 65():217-224. PubMed ID: 28546130
[TBL] [Abstract][Full Text] [Related]
11. Expression of T-cell immunoreceptor with immunoglobulin and tyrosine-based inhibitory motif domains (TIGIT) in anaplastic thyroid carcinoma.
Nakazawa T; Nagasaka T; Yoshida K; Hasegawa A; Guo F; Wu D; Hiroshima K; Katoh R
BMC Endocr Disord; 2022 Aug; 22(1):204. PubMed ID: 35971106
[TBL] [Abstract][Full Text] [Related]
12. TROP-2, 5hmC, and IDH1 Expression in Anaplastic Thyroid Carcinoma.
Seok JY; Astvatsaturyan K; Peralta-Venturina M; Lai J; Fan X
Int J Surg Pathol; 2021 Jun; 29(4):368-377. PubMed ID: 33289434
[TBL] [Abstract][Full Text] [Related]
13. Evidence that one subset of anaplastic thyroid carcinomas are derived from papillary carcinomas due to BRAF and p53 mutations.
Quiros RM; Ding HG; Gattuso P; Prinz RA; Xu X
Cancer; 2005 Jun; 103(11):2261-8. PubMed ID: 15880523
[TBL] [Abstract][Full Text] [Related]
14. CD10 is frequently expressed in classical seminomas.
Del Sordo R; Ascani S; Bellezza G; Ferri I; Sbaraglia M; Sidoni A
Histol Histopathol; 2014 Jan; 29(1):101-6. PubMed ID: 23857215
[TBL] [Abstract][Full Text] [Related]
15. Immunohistochemical expressions of fatty acid synthase and phosphorylated c-Met in thyroid carcinomas of follicular origin.
Liu J; Brown RE
Int J Clin Exp Pathol; 2011; 4(8):755-64. PubMed ID: 22135723
[TBL] [Abstract][Full Text] [Related]
16. Anaplastic thyroid carcinoma: an epidemiologic, histologic, immunohistochemical, and molecular single-institution study.
Deeken-Draisey A; Yang GY; Gao J; Alexiev BA
Hum Pathol; 2018 Dec; 82():140-148. PubMed ID: 30075157
[TBL] [Abstract][Full Text] [Related]
17. SPC24 is critical for anaplastic thyroid cancer progression.
Yin H; Meng T; Zhou L; Chen H; Song D
Oncotarget; 2017 Mar; 8(13):21884-21891. PubMed ID: 28423533
[TBL] [Abstract][Full Text] [Related]
18. Atypical adenoma of the thyroid diagnosed as anaplastic cancer by cytopathology.
Hatakeyama H; Hoshino K; Mizoguchi K; Suzuki T; Hatanaka KC; Yamaya Y; Kano S; Mizumachi T; Homma A
Diagn Cytopathol; 2017 Oct; 45(10):928-933. PubMed ID: 28544576
[TBL] [Abstract][Full Text] [Related]
19. CD10 Immunohistochemical Expression in Apocrine Lesions of the Breast.
Kővári B; Báthori Á; Cserni G
Pathobiology; 2015; 82(6):259-63. PubMed ID: 26562027
[TBL] [Abstract][Full Text] [Related]
20. IGF2BP1 is the first positive marker for anaplastic thyroid carcinoma diagnosis.
Haase J; Misiak D; Bauer M; Pazaitis N; Braun J; Pötschke R; Mensch A; Bell JL; Dralle H; Siebolts U; Wickenhauser C; Lorenz K; Hüttelmaier S
Mod Pathol; 2021 Jan; 34(1):32-41. PubMed ID: 32719445
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
